You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Applications

Our Abpromise guarantee covers the use of ab17550 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
Blocking BL: Use a concentration of 1 µg/ml.
  • Application notesThis peptide can be used with studies using ab10559.

    • Protein info

    • Alternative names
        B220CD 45CD45
        CD45 antigenCD45RGP180L CAL-CALCALeukocyte common antigenlocLy-5LY5Lyt-4OTTHUMP00000033813OTTHUMP00000033816OTTHUMP00000033817OTTHUMP00000038574Protein tyrosine phosphatase receptor type CProtein tyrosine phosphatase receptor type c polypeptideprotein tyrosine phosphatase, receptor type, CPTPRCPTPRC_HUMANReceptor-type tyrosine-protein phosphatase CSCID due to PTPRC deficiencyT200T200 glycoproteinT200 leukocyte common antigen
      see all
  • FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
  • Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
    Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
  • Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
    Contains 2 fibronectin type-III domains.
    Contains 2 tyrosine-protein phosphatase domains.
  • DomainThe first PTPase domain interacts with SKAP1.
  • Post-translational
    modifications    Heavily N- and O-glycosylated.
  • Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.

    • Target information above from: UniProt accession P08575 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt

    CD45 peptide images

    • WB - CD45 peptide
      WB - CD45 peptide

      ab10559  rabbit polyclonal to CD45  (1/500) with secondary goat anti-rabbit IgG ab6721 (1/5000).

      Expected molecular weight: 147 kDa. WB exposure time: 1min 30sec    

      Lanes 1 to 10: 20µg of cell lysate per lane
      Lanes 6 to 10: ab17550 CD45 blocking peptide used at 1µg/ml

      Lane 1: HeLa Nuclear Extract (ab10559)
      Lane 2: HeLa Whole Cell Lysate (ab10559)
      Lane 3: A431 Whole Cell Lysate (ab10559)
      Lane 4: Jurkat Whole Cell Lysate (ab10559)
      Lane 5: HEK293 Whole Cell Lysate (ab10559)
      Lane 6: HeLa Nuclear Extract (ab10559+ ab17550)
      Lane 7: HeLa Whole Cell Lysate (ab10559+ ab17550)
      Lane 8: A431 Whole Cell Lysate (ab10559+ ab17550)
      Lane 9: Jurkat Whole Cell Lysate (ab10559+ ab17550)
      Lane 10: HEK293 Whole Cell Lysate (ab10559+ ab17550)

      Binding of ab10559 to Jurkat cell lysate was blocked using ab17550.

    References for CD45 peptide (ab17550)

    ab17550 has not yet been referenced specifically in any publications.

    Publishing research using ab17550 ? Please let us know so that we can cite the reference in this datasheet

    Product Wall

    Submit an Abreview for ab17550 Submit a Question for ab17550

    Displaying 1 - 2 of 2 results for Abreviews and Q&A

    10
    Votes: Highest First

     Do you have the product number and price for the blocking peptide for ab103404? We are going to send you an order on that product and on some other products when we get that information.   Kind regards

    Thank you for contacting us. I apologize for the delay. The catalogue number of blocking peptide is ab116167. The price is £110 for 100 ug size. I hope this information is helpful to you. Please do not hesitate to contact us if you n...

    Read More

    Dear Sir/Madam 1)     We are doing western blot experiments for quantification. I read in the antibody guides that it would not be an advantage using polyclonals in quantification experiments. Is it absolutely not recommended using polyclonals when...

    Read More

    Thank you for contacting us. The positive controls for ab95023 are cell lysates of A-431, U2OS, U251 MG, Hela cell etc. Please click the following to see the positive control tissue lysates; http://www.proteinatlas.org/ENSG00000168685 ...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"